Silk Road Medical's stock rallies on Boston Scientific acquisition deal
By Steve Gelsi
Boston Scientific to pay double-digit premium to buy carotid-artery-disease treatment specialist.
Silk Road Medical Inc.'s stock was up 24% on Tuesday after it agreed to be acquired by Boston Scientific Corp. for $27.50 a share.
The deal values the Sunnyvale, Calif.-based medical device company (SILK) at just under $1.2 billion.
The price of $27.50 a share to be paid by Boston Scientific (BSX) amounts to a 27% premium over the closing price of $21.67 a share on Monday for Silk Road Medical's stock.
Boston Scientific said Silk Road Medical offers "an innovative platform of products to prevent stroke in patients with carotid artery disease."
Boston Scientific's stock rose about 0.1% .
Silk Road's board has approved the transaction and recommends shareholders approve the deal, which is expected to close by December.
Boston Scientific said Silk Road Medical is expected to generate up to 12% revenue growth this year - or up to $198 million.
The acquisition will start adding to Boston Scientific's earnings in 2026, the company said.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
06-18-24 1051ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations